eXoZymes NCTx Spinout Validates 100-Fold Scale-Up with 99.6% Purity
eXoZymes CCO Damien Perriman detailed the launch of its NCTx spinout to commercialize high-value natural products via cell-free biomanufacturing. Third-party partner Cayman Chemical scaled the NCT production process 100-fold, achieving approximately 99% conversion and 99.6% purity as proof of platform scalability.
1. Podcast Discussion on NCTx Strategy
eXoZymes CCO Damien Perriman appeared on the Grow Everything podcast to outline the rationale for spinning out NCTx as a dedicated commercialization vehicle for difficult-to-access molecules, while eXoZymes focuses on developing novel exozyme-based biomanufacturing processes.
2. Commercial Pathway for NCT
Perriman explained that NCTx will initially target the nutraceutical supplement market for its naturally occurring NCT molecule, citing existing preclinical interest, and will simultaneously evaluate longer-term pharmaceutical applications to broaden commercial opportunities.
3. Third-Party Validation and Scale-Up
In collaboration with Cayman Chemical, the NCT production process was independently transferred and scaled 100-fold, delivering approximately 99% conversion and 99.6% purity, providing a key proof point for the robustness and scalability of the cell-free platform.